Lonafarnib (SCH66336)

For research use only. Not for use in humans.

目录号:S2797

Lonafarnib (SCH66336) Chemical Structure

CAS No. 193275-84-2

Lonafarnib (SCH66336) 是一种口服生物有效的FPTase抑制剂,作用于H-rasK-ras-4BN-ras,无细胞试验中IC50分别为1.9 nM, 5.2 nM和2.8 nM。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 3509.73 现货
RMB 1416.91 现货
RMB 2229.57 现货
RMB 4250.61 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Lonafarnib (SCH66336)发表文献15篇:

客户使用该产品的2个实验数据:

  • Huh-7/hNTCP cells were infected with in vitro generated HDV in the presence or absence of MyrB (50 nM) or lonafarnib (200 nM). After 5 days cells were labeled with HDAg#280, secondary AF488 and stained with DAPI. A representative of four independent experiments is shown.

    Antiviral Res, 2017, 141:116-123. Lonafarnib (SCH66336) purchased from Selleck.

  • Low-dose lonafarnib decreased HIF-1α expression without inhibiting cell growth in MDA-MB-231 cells. (A, B) Lonafarnib (1 μM) treatment for 24 h significantly decreased HIF-1α expression, which was normalized to that of GAPDH. In contrast, lonafarnib (1 μM) did not decrease HIF-2α expression.

    J Cell Physiol, 2017, 232(1):192-201. Lonafarnib (SCH66336) purchased from Selleck.

产品安全说明书

Transferase抑制剂选择性比较

生物活性

产品描述 Lonafarnib (SCH66336) 是一种口服生物有效的FPTase抑制剂,作用于H-rasK-ras-4BN-ras,无细胞试验中IC50分别为1.9 nM, 5.2 nM和2.8 nM。Phase 3。
靶点
H-ras [1]
(Cell-free assay)
N-ras [1]
(Cell-free assay)
K-ras-4B [1]
(Cell-free assay)
1.9 nM 2.8 nM 5.2 nM
体外研究

SCH66336在0.1 μM到8 μM浓度范围均可抑制头部和颈部鳞状细胞癌(HNSCC) 生长和诱导凋亡,抑制效果具有剂量和时间依赖性。SCH66336 (8 μM)可在SqCC/Y1细胞中抑制蛋白激酶B/Akt活性和磷酸化 Akt蛋白底物糖原合酶激酶(GSK)- 3β,转录叉因子和BAD[2]。SCH66336 对多细胞系有抗增殖作用,IC 50范围从0.6 μM 到32.3 μM [3] ; Lonafarnib诱导CCAAT /增强子结合蛋白同源蛋白(CHOP)依赖性DR5启动子的转录激活,从而诱导CHOP依赖性的DR5上调。Lonafarnib (< 10 μM) 可激活caspase - 8及其下游的半胱氨酸蛋白酶,从而诱导H1792细胞凋亡。Lonafarnib (5 μM)可增加DR5的细胞表面分布,增强肿瘤坏死因子相关凋亡诱导配体诱导的H1792细胞凋亡[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Cos-1 monkey kidney cells M2LWfmZ2dmO2aX;uJIF{e2G7 MV7Jcohq[mm2aX;uJI9nKFC{b4TlbY4h\mG{bnXzfYx1emGwc3\ldoF{\SCrbjDDc5MuOSCvb37r[Zkhc2mmbnX5JINmdGy|IHX4dJJme3OrbnegTE1T[XNvdnHsMEBKSzVyPUCuNFAyQSEQvF2= NHPFPVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMxQSd-MUKxPVA{ODl:L3G+
COS-7 monkey cells NIPYfJVHfW6ldHnvckBie3OjeR?= NXPT[pE5UW6qaXLpeIlv\yC2aHWg[oFzdmW|eXzheIlwdiCxZjDIMZJieyCycn;0[YlveyCrbjDDU3MuPyCvb37r[Zkh[2WubIOgeJJidnOrZX70cJkh\XiycnXzd4lv\yCKLYLhd3tX[WxzMm2tR3ZNWyCrbjD0bIUhf2ixbHWgZ4VtdCCjc4PhfUwhUUN3ME2wMlAyKM7:TR?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86QDJ{NUW4K|46QDJ{NUW4QE9iRg>?
MCF-7 tumor cell line NIjzTJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4GzO2NwdXCxdX7kJJdieyCvZXHzeZJm\CCob4KgbY5pcWKrdHnvckBw\iCPQ1[tO{B1fW2xcjDj[YxtKGyrbnWgbY4h[nKnYYP0JJVv\GW{IIPv[pQh[WejcjDhd5NigSxiSVO1NF0xNjB3IN88US=> NVLoUIZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUiyNlU2QCd-OUiyNlU2QDxxYU6=
HCT116 MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlTwR49ueG:3bnSge4F{KG2nYYP1doVlKG[xcjDpcohq[mm2aX;uJI9nKEiFVEGxOkB1fW2xcjDj[YxtKGyrbnWgbY4h[2:ub36geY5l\XJic3;meEBi\2G{IHHzd4F6NCCLQ{WwQVAvODdizszN M2DzUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl6MkK1OVgoRjl6MkK1OVg9N2F-
NIH-H tumor cell lines MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWGydYg1S2:vcH;1coQh[WKrbHn0fUB1dyCrbnjpZol1KGGwY3jvdoFo\S2rbnTldIVv\GWwdDDndo94fGhib3[gUmlJNUhidIXtc5Ih[2WubDDsbY5meyCrbjDzc4Z1KGGpYYKsJGlEPTB;MD6wO|Ih|ryP NYXTWIZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUiyNlU2QCd-OUiyNlU2QDxxYU6=
NIH3T3 cells MWTGeY5kfGmxbjDhd5NigQ>? MVHJcohq[mm2aX;uJI9nKFKjczDmZZJv\XO7bHH0bY9vKGmwIFitVoF{KHS{YX7z[o9zdWWmIF7JTFNVOyClZXzsd{whTUN3ME2wMlEh|ryP NVPrS4V6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW0OVQzOjhpPkG1OFU1OjJ6PD;hQi=>
NIH-K tumor cell lines MljFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnjMR49ueG:3bnSgZYJqdGm2eTD0c{BqdmirYnn0JIFv[2ixcnHn[U1qdmSncHXu[IVvfCCpcn;3eIghd2ZiTlnIMWshfHWvb4KgZ4VtdCCuaX7ld{BqdiC|b3\0JIFo[XJuIFnDOVA:OC53IN88US=> NVHo[WV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUiyNlU2QCd-OUiyNlU2QDxxYU6=
Cos-1 MnPoSpVv[3Srb36gZZN{[Xl? NVKyN2p[UW6qaXLpeIlwdiCxZjDQdo91\WmwIH\hdo5me3mudILhcpNn\XKjc3WgbY4hS2:|LUGgcY9vc2W7IHvp[I5mgSClZXzsd{BmgHC{ZYPzbY5oKEhvUnHzMZZidCxiSVO1NEA:KDBwMECxPUDPxE1w NHnzemc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMxQSd-MUKxPVA{ODl:L3G+
Cos-1 M{LXdGZ2dmO2aX;uJIF{e2G7 M3TDR2Vn\mWldDDvckBT[XNicILvZ4V{e2mwZzDpckBEd3NvMTDtc45s\Xlia3nkcoV6KGOnbHzzJIV5eHKnc4Ppcoch\Wm2aHXyJGguWmG|LW\hcEAyOi2FVlzTJI9zKEhvUnHzMXZidDF{LDDJR|UxKD1iMD6wNUDPxE1w NHPXUIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMESxNVQ5PSd-MUC0NVE1QDV:L3G+
COS7 M3Hnc2Z2dmO2aX;uJIF{e2G7 MVPJcohq[mm2aX;uJI9nKE[WYYPlJIlvKGi3bXHuJGNQWzdiY3XscJMtKEmFNUCgQUAxNjBzIN88UU4> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl{NUSzN{c,OjB7MkW0N|M9N2F-
H-Ras transformed cells M1TGcmZ2dmO2aX;uJIF{e2G7 NFHkSVFKdmirYnn0bY9vKG:oIIPv[pQh[WejcjDjc4xwdnliZn;ycYF1cW:wIHnuJGguWmG|IITyZY5{\m:{bXXkJINmdGy|LDDJR|UxKD1iMD6wO{DPxE1w MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTVyMUC2OUc,OTV3MEGwOlU9N2F-
NIH3T3 MWLGeY5kfGmxbjDhd5NigQ>? M2fucmVn\mWldHn2[UBkd26lZX70doF1cW:wIHHnZYlve3RiSHGtVmFUKHC{b3Pld5NqdmdiaX6gUmlJO1R|IILhd{11emGwc3\vdo1m\CClZXzsd{whTUN3MDC9JFAvOTZizszNMi=> M4PkfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkW3Nlg1Lz5zMk[1O|I5PDxxYU6=
NIH3T3 M2KxfWZ2dmO2aX;uJIF{e2G7 MlfzWHBgXFKDTmPQU3JVTVJ8IHnubIljcXSrb36gc4YhTE6UIHXm[ox2gCBqRF7SPkA0KHWPKTDpckBOTFJzLXX4dJJme3OrbnegUmlJO1R|IHPlcIx{NCCLQ{WwJF0hOi55IN88UU4> M{ex[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNkC2N|g6Lz5zMU[wOlM5QTxxYU6=
A673 M2jjbZFJXFNiYYPzZZk> MlP2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY MYXxTHRUKGG|c3H5 MnnBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NFrETW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 MXTxTHRUKGG|c3H5 NV:5fWI3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> MlHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 NWrhOZFmeUiWUzDhd5NigQ>? MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? Mni4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD NWj1SZUzeUiWUzDhd5NigQ>? NYLaTog4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| NYn4RXNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 M1TtV5FJXFNiYYPzZZk> NGK3XINyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= MkPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) MYfxTHRUKGG|c3H5 NXztdo97eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz Mk\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 NV7xUY5keUiWUzDhd5NigQ>? MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| NVnGTWh6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 MXHxTHRUKGG|c3H5 M4TOT5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 M135N5FJXFNiYYPzZZk> M4rVVJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| MmDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 M2SzRZFJXFNiYYPzZZk> Mnf1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MoezdWhVWyCjc4PhfS=> MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NWTMfZI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 Mnj5dWhVWyCjc4PhfS=> MnKxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 NUX1[FVOeUiWUzDhd5NigQ>? M3nKbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Caco-2 NVjBVnp7S3m2b4TvfIlkcXS7IHHzd4F6 M1;0SlQ5KGixdYLz NGC0S5JF\XSncn3pcoF1cW:wIH;mJGlEPTBidnHseYV{KG[xcjDpcohq[mm2aX;uJI9nKFODUmOtR49XNTJiaX7keYNm\CCleYTveI95cWOrdImgc4YhS2Glbz2yJINmdGy|IHHmeIVzKDR6IHjveZJ{KGK7IHjp[4gh[2:wdHXueEBqdWGpaX7nMEBKSzVyIE2gOU43QCEQvF2u Ml;JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlk5PzN2Lze+R4hGVUKOPD;hQi=>
Caco-2 NEG0Z|JVd3irY3n0fUBie3OjeR?= NWf0coJwPDhiaH;1dpM> M1XZ[XRwgGmlaYT5JIFo[Wmwc4SgR4Fkdy1{IHPlcIx{KGSndHXycYlv\WRiYYSgOFghcG:3coOgZpkhcW62cnHj[YxtfWyjcjDBWHAh[2:wY3XueJJifGmxbjD1d4lv\yC2aHWgR4VtdFSrdHXyMWdtdyCOdX3pcoV{[2WwdDDD[YxtKF[rYXLpcIl1gSCDc4PhfUwhS0N3MDC9JFExNjdzIN88UU4> NVTBfoRHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjl6N{O0M{c,S2iHTVLMQE9iRg>?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3A / LC3B ; 

PubMed: 29069775     


Lonafarnib, inhibitor for farnesyl transferase, significantly induced the expression of autophagy marker.

Cyclin D / CDK6 / CDK4 / SKP2; 

PubMed: 29285232     


Western blot analysis of levels of cell cycle-related proteins including Cyclin D, CDK4, CDK6 and SKP2 in HCC cells treated with lonafarnib as indicated.

PARP / cleaved-PARP / pro-caspase3 / cleaved-caspase3 / Bcl-2; 

PubMed: 29285232     


Western blot analysis of levels of apoptosis-related protein including PARP, cleaved PARP, pro-Caspase-3, cleaved Caspase-3 and Bcl-2 in HCC cells treated with lonafarnib as indicated. The asterisk indicates a non-specific band.

p-ERK / p-SAPK / p-JNK; 

PubMed: 29285232     


Western blot analysis of protein levels of phosphoERK1/2, phospho-SAPK/JNK, total ERK1/2 and total SAPK/JNK in HCC cells treated with lonafarnib as indicated.

29069775 29285232
Growth inhibition assay
Cell viability; 

PubMed: 15860663     


PLC1 cells were treated with the indicated concentrations of SCH66336 for the indicated amount of time. Viability is expressed as the percentage of trypan blue-excluding cells of the total number of cells present. 

Cell number; 

PubMed: 29069775     


Lonafarnib, inhibitor for farnesyl transferase, significantly inhibited the cell proliferation. 

15860663 29069775
体内研究 SCH66336 抑制HTBI77人肺癌裸鼠移植模型中的瘤生长,抑制作用呈剂量依赖性[1]。在NOD/SCID免疫缺陷小鼠皮下注射XEN01, XEN05或XEN08 GBM建立肿瘤移植模型,SCH66336 以 50 mg/kg剂量口服灌胃21天后,可抑制肿瘤生长,抑制率高达69%[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[2]
- 合并
  • Cell lines: UMSCC10B, UMSCC14B, UMSCC17B, UMSCC22B, 和UMSCC35, UMSCC38 细胞
  • Concentrations: 0.1 μM - 8 μM
  • Incubation Time: 24 小时
  • Method: 细胞铺板于96孔板中,后续培养5天,据此确定起始密度。24小时后,用不同浓度SCH66336处理细胞。SCH66336溶解于DMSO。对照组细胞用同样量的DMSO处理。5天后用SRB法检测细胞数量。生长抑制的百分比的计算公式为:增长抑制百分比=(1−/At/Ac)×100,At和Ac分别代表实验组和对照组的吸收值。IC 50值由剂量反应曲线确定。
    (Only for Reference)
动物实验:[3]
- 合并
  • Animal Models: 6–12周龄NOD/SCID 小鼠
  • Dosages: 50 mg/kg
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 127 mg/mL (198.8 mM)
Water Insoluble
Ethanol '127 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 638.82
化学式

C27H31Br2ClN4O2

CAS号 193275-84-2
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02579044 Enrolling by invitation Drug: Everolimus and lonafarnib Progeria Boston Children''s Hospital December 2015 Phase 1|Phase 2
NCT02527707 Completed Drug: lonafarnib|Drug: Ritonavir Chronic Delta Hepatitis Eiger BioPharmaceuticals|Hannover Medical School September 2015 Phase 2
NCT02430194 Completed Drug: lonafarnib|Drug: Ritonavir|Drug: PEG IFN-a Chronic Hepatitis D Infection Eiger BioPharmaceuticals|Ankara University December 2014 Phase 2
NCT02430181 Completed Drug: lonafarnib|Drug: PEG IFN-a|Drug: Ritonavir Chronic Hepatitis D Infection Eiger BioPharmaceuticals November 2014 Phase 2
NCT01495585 Completed Drug: Lonafarnib|Other: Placebo Hepatitis D National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) December 2011 Phase 2
NCT01232881 Terminated Procedure: Tumor Sample|Procedure: Serum Sample Breast Cancer Hoosier Cancer Research Network|United States Department of Defense|Indiana University School of Medicine|Emory University August 2009 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Transferase Signaling Pathway Map

Tags: 购买Lonafarnib (SCH66336) | Lonafarnib (SCH66336)供应商 | 采购Lonafarnib (SCH66336) | Lonafarnib (SCH66336)价格 | Lonafarnib (SCH66336)生产 | 订购Lonafarnib (SCH66336) | Lonafarnib (SCH66336)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID